NAFLD - A rising metabolic disease.
作者信息
Zeigerer Anja
机构信息
Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
出版信息
Mol Metab. 2021 Aug;50:101274. doi: 10.1016/j.molmet.2021.101274. Epub 2021 Jul 2.
Abstract
摘要
相似文献
1
NAFLD - A rising metabolic disease.非酒精性脂肪性肝病——一种日益常见的代谢性疾病。
Mol Metab. 2021 Aug;50:101274. doi: 10.1016/j.molmet.2021.101274. Epub 2021 Jul 2.
2
Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).随着我们从单纯性非酒精性脂肪性肝病（NAFLD）时代过渡到代谢相关脂肪性肝病（DAFLD）时代，NAFLD 取得了进展。
Metabolism. 2020 Oct;111S:154318. doi: 10.1016/j.metabol.2020.154318. Epub 2020 Jul 21.
3
From circadian clocks to non-alcoholic fatty liver disease.从生物钟到非酒精性脂肪性肝病。
Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1107-1112. doi: 10.1080/17474124.2019.1684899. Epub 2019 Oct 30.
4
Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.发现一种用于治疗代谢功能障碍相关脂肪性肝病的选择性细胞色素P450 4A抑制剂。
Clin Transl Med. 2024 Oct;14(10):e1816. doi: 10.1002/ctm2.1816.
5
Obstructive Sleep Apnea Syndrome and Metabolic Diseases.阻塞性睡眠呼吸暂停综合征与代谢性疾病。
Endocrinology. 2018 Jul 1;159(7):2670-2675. doi: 10.1210/en.2018-00248.
6
Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance.高脂饮食对啮齿动物肝脏生物能量学及氧化失衡的影响。
Redox Biol. 2016 Aug;8:216-25. doi: 10.1016/j.redox.2016.01.009. Epub 2016 Jan 14.
7
Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.代谢相关脂肪性肝病患者中胰高血糖素样肽-1 受体激动剂疗效的比较：更新的系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 Feb 16;11:622589. doi: 10.3389/fendo.2020.622589. eCollection 2020.
8
Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.利拉鲁肽可改善非酒精性脂肪性肝炎 3 周饮食诱导的小鼠模型中的肝脂肪变性和代谢功能障碍。
Am J Physiol Gastrointest Liver Physiol. 2019 Oct 1;317(4):G508-G517. doi: 10.1152/ajpgi.00139.2019. Epub 2019 Aug 28.
9
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.二肽基肽酶-4抑制剂替格列汀通过激活非酒精性脂肪性肝病模型小鼠的AMPK减轻肝脏脂肪生成。
Int J Mol Sci. 2015 Dec 8;16(12):29207-18. doi: 10.3390/ijms161226156.
10
HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.HCBP6 缺乏加剧非酒精性脂肪肝小鼠的糖脂代谢紊乱。
Biomed Pharmacother. 2020 Sep;129:110347. doi: 10.1016/j.biopha.2020.110347. Epub 2020 Jun 11.
引用本文的文献
1
Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases.用于治疗人类疾病的组蛋白去乙酰化酶抑制剂创制的最新见解
Int J Mol Sci. 2025 Sep 4;26(17):8629. doi: 10.3390/ijms26178629.
2
Causal association between macrophage migration inhibitory factor and nonalcoholic fatty liver disease: A two-sample Mendelian randomization study.巨噬细胞移动抑制因子与非酒精性脂肪性肝病之间的因果关联：一项两样本孟德尔随机化研究。
Medicine (Baltimore). 2025 Sep 5;104(36):e44106. doi: 10.1097/MD.0000000000044106.
3
Diagnostic value of serologic biomarkers for the detection of liver fibrosis in non-alcoholic fatty liver disease.血清生物标志物在非酒精性脂肪性肝病肝纤维化检测中的诊断价值
Caspian J Intern Med. 2025 Mar 11;16(2):275-283. doi: 10.22088/cjim.16.2.275. eCollection 2025.
4
Potential diagnostic marker gene set for non-alcoholic steatohepatitis associated hepatocellular carcinoma with lymphocyte infiltration.与淋巴细胞浸润相关的非酒精性脂肪性肝炎相关肝细胞癌的潜在诊断标志物基因集。
Transl Cancer Res. 2025 Apr 30;14(4):2274-2289. doi: 10.21037/tcr-2024-2291. Epub 2025 Apr 25.
5
TRIB3 Is a Hub Gene in Steatohepatitis and Aggravates Lipid Deposition and Inflammation in Hepatocytes.TRIB3是脂肪性肝炎中的一个枢纽基因，可加重肝细胞中的脂质沉积和炎症。
Diabetes Metab Syndr Obes. 2025 Apr 15;18:1111-1124. doi: 10.2147/DMSO.S486377. eCollection 2025.
6
Bioinformatic analysis of molecular expression patterns during the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD).代谢功能障碍相关脂肪性肝病（MASLD）发生发展过程中分子表达模式的生物信息学分析
Sci Rep. 2025 Mar 1;15(1):7294. doi: 10.1038/s41598-025-90744-3.
7
Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD.使用高选择性抑制剂靶向组蛋白去乙酰化酶11治疗代谢相关脂肪性肝病。
Adv Sci (Weinh). 2025 Apr;12(15):e2412903. doi: 10.1002/advs.202412903. Epub 2025 Feb 20.
8
Predictors of Atherosclerotic Cardiovascular Disease Events in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.代谢功能障碍相关脂肪性肝病患者动脉粥样硬化性心血管疾病事件的预测因素
Intern Med. 2025 Jun 15;64(12):1791-1798. doi: 10.2169/internalmedicine.4373-24. Epub 2024 Nov 21.
9
Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease.血清细胞角蛋白18片段是治疗代谢功能障碍相关脂肪性肝病的一个指标。
Gastro Hep Adv. 2024 Aug 14;3(8):1120-1128. doi: 10.1016/j.gastha.2024.08.008. eCollection 2024.
10
Global trends and emerging topics related to triglyceride-glucose index: A bibliometric analysis and visualization from 2000 to 2024.全球与甘油三酯-葡萄糖指数相关的趋势和新兴主题：2000 年至 2024 年的文献计量分析和可视化。
Medicine (Baltimore). 2024 Oct 4;103(40):e39916. doi: 10.1097/MD.0000000000039916.
Zotero 插件